Background Over the past decade, advances in next-generation sequencing (NGS) have decreased cost and enabled more widespread use in solid tumor oncology. This has been accompanied by increasing therapeutic options based on tumor genomic profiling
Search Results
Alexandra O. Sokolova, Brian H. Shirts, Eric Q. Konnick, Ginger J. Tsai, Bernardo H.L. Goulart, Bruce Montgomery, Colin C. Pritchard, Evan Y. Yu, and Heather H. Cheng
Tarra Evans and Ursula Matulonis
. Mardis ER . Next-generation DNA sequencing methods . Annu Rev Genomics 2008 ; 9 : 387 – 402 . 3. Hagemann IS Fuchs S Monoranu CM . Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy . Cancer
Luxi Chen, John Davelaar, Srinivas Gaddam, Kambiz Kosari, Nicholas Nissen, George Chaux, Christopher Lee, Eric Vail, Andrew Hendifar, Jun Gong, Karen Reckamp, and Arsen Osipov
weeks following stent placement, the patient’s CA 19-9 level was 97 U/mL. At the time of initial diagnostic biopsy, next-generation sequencing (NGS) was obtained via Tempus Laboratories, Inc. Staging CT scan of the chest showed suspicious spiculated
Kristin K. Deeb, Jakub P. Sram, Hanlin Gao, and Marwan G. Fakih
mutation, such as KRAS , to a more comprehensive assessment of genomic alterations. This review describes next-generation sequencing (NGS)-based multigene assays in clinical practice, their distinct advantages, and their limitations. Application of
Christie Hancock and Jacob Bitran
Background: The value of next-generation sequencing (NGS) tests is dependent on how it changes clinical management, if at all. There are not any guidelines on when a physician should obtain testing; what certain genetic variations can be clinically
Andrew W. Hahn, Smith Giri, Dilan Patel, Heather Sluder, Ari Vanderwalde, and Mike G. Martin
small clinical trials. 5 The availability of next-generation sequencing (NGS) has made it feasible for clinicians to analyze genetic profiles of an individual's cancer. When these results are coupled with the continual development of targeted therapies
Kaushal Desai, Gillian Hooker, Gboyega Adeboyeje, Sumesh Kachroo, and Shuvayu Sankar Sen
Background: Next-Generation Sequencing (NGS) based genomic testing is one of the key drivers of precision medicine in US Oncology practices. Studies of utilization of NGS testing via insurance claims have been challenged by widely variable and
Szu-Chun Yang, Yi-Chen Yeh, Yi-Lin Chen, and Chao-Hua Chiu
for the treatment of patients with these gene alterations. Next-generation sequencing (NGS) can test all these actionable gene alterations and has emerged on the front line to guide appropriate therapy. In Western countries, where none of these 8
Natasha Hunter, Sarah Croessmann, Karen Cravero, Daniel Shinn, Paula J. Hurley, and Ben Ho Park
digital PCR (ddPCR) and ultra-deep next-generation sequencing (NGS), clinicians are able to track tumor burden, evaluate response to therapies, and detect MRD using cancer DNA alterations present in cfDNA as a biomarker. Indeed, many studies have supported
angioimmunoblastic T-cell lymphoma (AITL). Figure 1. Patient case study 1: results of further testing. Abbreviations: NGS, next-generation sequencing; RUL, right upper lobe; SUV, standard uptake value; VATS, video-assisted thoracic surgery. Dr. Advani explained that
